American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

article

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JOMS.2014.04.031
P698PubMed publication ID25234529

P50authorThomas B DodsonQ95336517
John E FantasiaQ98936044
P2093author name stringTara Aghaloo
Bhoomi Mehrotra
Reginald Goodday
Felice O'Ryan
Salvatore L. Ruggiero
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectposition paperQ7233193
P304page(s)1938-1956
P577publication date2014-10-01
P1433published inJournal of Oral and Maxillofacial SurgeryQ6295692
P1476titleAmerican Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
P478volume72

Reverse relations

cites work (P2860)
Q36340765A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors
Q42319484A Case of Bisphosphonate-Related Osteonecrosis of the Jaw in a Patient with Subpontic Osseous Hyperplasia
Q38468208A Case of Brain Abscess Caused by Medication-Related Osteonecrosis of the Jaw.
Q47120536A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab
Q40064245A Case of Pentastomiasis at the Left Maxilla Bone in a Patient with Thyroid Cancer.
Q91962788A Novel, Tumor-Induced Osteoclastogenesis Pathway Insensitive to Denosumab but Interfered by Cannabidiol
Q55256056A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis.
Q57459606A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw
Q47252665A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer
Q87940374A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent M
Q90392351A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
Q36360226A rare case of osteonecrosis of the jaw related to imatinib
Q40490169A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians
Q64989421A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015.
Q36760348Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
Q64935046Adipose-derived stem cells prevent the onset of bisphosphonate-related osteonecrosis of the jaw through transforming growth factor β-1-mediated gingival wound healing.
Q39130990Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.
Q90066061Adjuvant denosumab in early breast cancer - Authors' reply
Q90014839Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review
Q53773544Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.
Q88466609Aggressive denosumab-related jaw necrosis - a case series
Q60910319Allogeneic multipotent mesenchymal stromal cell sheet transplantation promotes healthy healing of wounds caused by zoledronate and dexamethasone in canine mandibular bones
Q52663393Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Q42290498An elderly with a 'bony' smile
Q102059139An impossible choice: MRONJ vs ORN? The difficulties of the decision-making process for head and neck cancer patients on long-term anti-angiogenic medication
Q41019775An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats.
Q41570205An unusual case of disappearing bone disease in the mandible and literature review
Q39029480Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates
Q35906730Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events
Q55265048Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.
Q55244759Anti-inflammatory effect of polydeoxyribonucleotide on zoledronic acid-pretreated and lipopolysaccharide-stimulated RAW 264.7 cells.
Q91671918Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
Q30239854Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
Q90145052Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients
Q47732074Antiresorptive treatment-associated ONJ.
Q36753894Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents
Q89921984Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners
Q27026718Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral [...]
Q39299999Beyond ONJ - A review of the potential uses of bisphosphonates in dentistry
Q91974441Bilateral Bone Ridge Splitting in Maxilla with Immediate Implant Placement in a Patient with Osteoporosis: A Clinical Report with 2-Year Follow-up
Q41366615Bilateral Maxillary Reconstruction Using Fibular Flap in Bisphosphonate-related Osteonecrosis
Q38538490Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare
Q39034377Biomarkers for Bisphosphonate-Related Osteonecrosis of the Jaw.
Q61453146Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review
Q37087037Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism
Q51743699Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
Q35877630Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking
Q48283228Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
Q39367690Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males
Q37217791Bisphosphonate treatment and dental implants: A systematic review
Q35755688Bisphosphonate uptake in areas of tooth extraction or periapical disease
Q36299558Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation
Q37626921Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report
Q36426563Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report
Q36527045Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases
Q55364153Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective.
Q31108809Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database
Q38831851Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.
Q92976897Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model
Q48136150Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
Q38970807Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Q60673746Bone-Targeted Agents
Q47557023CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws.
Q41607133Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?
Q39062020Carcinoma of the lip five years after bone marrow transplantation
Q58753629Case report of maxillofacial fracture in a patient under bisphosphonates in the absence of ONJ disease: Guidelines?
Q52572107Changes in dimension of neurovascular canals in the mandible and maxilla: A radiographic finding in patients diagnosed with MRONJ.
Q55368042Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration.
Q36604330Chemical and Radiation-Associated Jaw Lesions
Q92514560Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China
Q92504999Clinical and panoramic radiographic features of osteomyelitis of the jaw: A comparison between antiresorptive medication-related and medication-unrelated conditions
Q58595822Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw
Q55032991Clinical impact of bisphosphonates in root canal therapy.
Q89598542Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population
Q47297530Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid
Q90353077Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws
Q38490996Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus".
Q90676907Comparison of Isoflurane, Ketamine-Dexmedetomidine, and Ketamine-Xylazine for General Anesthesia during Oral Procedures in Rice Rats (Oryzomys palustris)
Q48093177Comparison of effects of zoledronic acid and clodronate on the bone structure: imaginological and histomorphometrical study in vivo
Q88431996Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study
Q92504991Computer programme to assess mandibular cortex morphology in cases of medication-related osteonecrosis of the jaw with osteoporosis or bone metastases
Q38716842Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature
Q49858723Conservative Prosthetic Rehabilitation of Medication-Related Osteonecrosis of the Jaw (MRONJ).
Q58766046Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study
Q96962756Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study
Q54500167Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.
Q34815134Current controversies in classification, management, and prevention of bisphosphonate-related osteonecrosis of the jaw.
Q90122423Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals
Q57152356Cytokine Mixtures Mimicking Secretomes From Mesenchymal Stem Cells Improve Medication-Related Osteonecrosis of the Jaw in a Rat Model
Q40332532DC-STAMP Is an Osteoclast Fusogen Engaged in Periodontal Bone Resorption.
Q64966398Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients.
Q90714435Deciphering novel chemotherapy and its impact on dentistry
Q87430852Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?
Q55094789Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.
Q37246486Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case.
Q91999745Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial
Q91013795Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Q89052349Denosumab treatment in postmenopausal women with osteoporosis
Q49917811Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply
Q88310017Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
Q36524611Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases
Q38660112Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
Q47251973Denosumab-related osteonecrosis of the jaw: A retrospective study.
Q91675370Dental care for patients taking antiresorptive drugs: a literature review
Q37713115Dental extraction following zoledronate, induces osteonecrosis in rat's jaw.
Q38262448Dental implants in patients affected by systemic diseases
Q28080315Dental implants in patients treated with antiresorptive medication - a systematic literature review
Q47149046Dental students' knowledge of medication-related osteonecrosis of the jaw.
Q39636360Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study
Q98226363Dentists' knowledge about medication-related osteonecrosis of the jaw and its management
Q37123301Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
Q47336736Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw.
Q37408215Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw.
Q57218212Distribution of medical status and medications in elderly patients treated with dental implant surgery covered by national healthcare insurance in Korea
Q46146438Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?
Q53815592EU/IT Multicenter Studies (ON/OFF) and the “DoctOral” System for ONJ.
Q48172033Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice
Q87422028Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis
Q39434824Effect of local zoledronate delivery on osseointegration: a systematic review of preclinical studies
Q50033823Effects of Zoledronic Acid in Experimental Periapical Lesions in Rats: An Imaging and Histological Analysis.
Q64277342Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats: A preliminary macroscopic and microscopic quantitative study
Q94565079Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
Q96431150Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature
Q91892086Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy
Q94571272Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw
Q61810541Epidermal Growth Factor Reverses the Inhibitory Effects of the Bisphosphonate, Zoledronic Acid, on Human Oral Keratinocytes and Human Vascular Endothelial Cells In Vitro via the Epidermal Growth Factor Receptor (EGFR)/Akt/Phosphoinositide 3-Kinase (P
Q36839105Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT.
Q53808348Evaluation of a new visual aid for the identification of oral mucosal diseases and conditions.
Q87273229Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients
Q53242939Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis.
Q38624057Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics
Q64265907Extensive osteonecrosis of the maxilla caused by bisphosphonates: Report of a rare case
Q90499876Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Q40690834Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw.
Q90567724From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights
Q64070933Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis
Q92859165General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of Eng
Q50926376Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid.
Q35590055How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network
Q38803408Hyperbaric oxygen therapy and osteonecrosis
Q40605141IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-β-Mediated Collagen Expression.
Q91788229Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan
Q52909564Image findings of bisphosphonate related osteonecrosis of jaws comparing with osteoradionecrosis.
Q54958018Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ).
Q64081078Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan
Q89341835Imaging of Radiation- and Medication-Related Osteonecrosis
Q91608582Immediate reconstruction of mandibular defect after treatment of medication-related osteonecrosis of the jaw (MRONJ) with rhBMP-2/ACS and miniplate: Review of 3 cases
Q40696253Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group
Q47363538In-vivo imaging of the microvasculature of the soft tissue margins of osteonecrotic jaw lesions
Q89795058Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease
Q47672449Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors
Q47325841Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Q89936409Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis
Q49824107Influence of the teaching program on the learning in knowledge and practice of osteonecrosis of the jaws produced by antireasorptives in dental students of the Principality of Asturias (Spain).
Q38393256International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
Q51273538Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.
Q42695284Interventions for managing medication-related osteonecrosis of the jaw.
Q47705261Investigation of dental cone-beam CT pixel data and a modified method for conversion to Hounsfield unit (HU).
Q85476262Jaw problems: Update on ARONJ
Q89596946Knowledge and Opinions of Saudi Dentists Regarding Dental Treatment of Patients Undergoing Bisphosphonates
Q41253737Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw.
Q28583668Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists
Q50041551Laser and Platelet-Rich Plasma to treat Medication-Related Osteonecrosis of the Jaws (MRONJ): a case report
Q89396612Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study
Q90047306Low-Intensity Pulsed Ultrasound Prevents Development of Bisphosphonate-Related Osteonecrosis of the Jaw-Like Pathophysiology in a Rat Model
Q52672755Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw.
Q49836028MRONJ risk of adjuvant bisphosphonates in early stage breast cancer
Q53646302MRONJ risk reduction pathway - 360 degree survey.
Q35570290Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.
Q91060388Management of bone complications in patients with genitourinary malignancies
Q38756478Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview
Q64965457Managing tooth pain in general practice.
Q41844679Maxilla Osteonecrosis: a differential diagnosis in patients with metastatic cancer on bisphosphonates
Q33703167Meaning and Limitation of Cortical Bone Width Measurement with DentaScan in Medication-Related Osteonecrosis of the Jaws
Q89308700Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings
Q36144427Medication-Related Osteonecrosis of Jaws: A Low-Level Laser Therapy and Antimicrobial Photodynamic Therapy Case Approach.
Q28072449Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches
Q37397060Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience.
Q64078469Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies
Q90449869Medication-related Osteonecrosis of the Jaw: A Review
Q64276494Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat
Q58600670Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study
Q52985345Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Q64082139Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review
Q39700905Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model.
Q52630017Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Q26749965Medication-related osteonecrosis of the jaw: Clinical and practical guidelines
Q64982389Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization.
Q42324262Medication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors
Q48238647Medication-related osteonecrosis of the posterior maxilla: surgical treatment using a combined transnasal endoscopic and intraoral approach, our experience with seven consecutive patients
Q92564261Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw
Q57053962Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw
Q64076859Microcirculatory consequences of limb ischemia/reperfusion in ovariectomized rats treated with zoledronic acid
Q37613671Microscopic Evaluation of the Effect of Oral Microbiota on the Development of Bisphosphonate-Related Osteonecrosis of the Jaws in Rats
Q55426041Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review.
Q55077666Minodronate for the treatment of osteoporosis.
Q90482843Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors
Q39178336Modified protocol including topical minocycline in orabase to manage medication-related osteonecrosis of the jaw cases
Q97538215Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients
Q36766324National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
Q56984566Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report
Q98564875New MRONJ guidance
Q60922830Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts
Q89187407Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care
Q64266454Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Q37199204OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
Q38585389Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis
Q47567474Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review
Q59465735Oral and dental health in head and neck cancer survivors
Q90465321Oral health status of patients with multiple myeloma
Q38948950Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Q88557131Oral rehabilitation of the cancer patient: A formidable challenge
Q40205778Oral squamous cell carcinoma arising in a patient after hematopoietic stem cell transplantation with bisphosphonate-related osteonecrosis of the jaws
Q50061924Oral surgery: The drug holiday
Q47629480Osseous changes in patients with medication-related osteonecrosis of the jaws
Q26827072Osteochemonecrosis: an overview
Q38807483Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology
Q52643968Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.
Q55332559Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature.
Q35837168Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY.
Q52620697Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India.
Q90116722Osteonecrosis of the Jaw and Concomitant Atypical Femoral Fractures with Bisphosphonates: A Comprehensive Literature Review
Q57163245Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology
Q40560466Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases
Q41470599Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Q55346257Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.
Q47941432Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Q35818022Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.
Q38865775Osteonecrosis of the jaw a new complication related to Ipilimumab.
Q42373317Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark
Q37525339Osteonecrosis of the jaw associated with ziv-aflibercept
Q51071178Osteonecrosis of the jaw in a patient receiving cabozantinib.
Q88527999Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis
Q36667402Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients
Q37036742Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
Q57800097Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review
Q42202161Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease
Q99240570Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
Q61450539Osteonecrosis of the jaws caused by bisphosphonate treatment and oxidative stress in mice
Q64277201Osteonecrosis of the jaws produced by sunitinib: a systematic review
Q34541797Osteoporosis and Periodontitis
Q39185692Otorhinolaryngological Toxicities of New Drugs in Oncology
Q100761762Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw
Q58791940Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials
Q37006852Pathophysiology of Osteonecrosis of the Jaws
Q64070481Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England
Q36125581Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw.
Q38691628Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws
Q92557680Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Q41161756Plasticity of Myeloid Cells during Oral Barrier Wound Healing and the Development of Bisphosphonate-related Osteonecrosis of the Jaw.
Q48231013Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study
Q34512454Position paper on medication-related osteonecrosis of the jaw (MRONJ)
Q40509688Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction-induced Bisphosphonate-related Osteonecrosis of the Jaw Lesions in Mice.
Q56525024Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw
Q57802320Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis
Q42017254Prevention of breast cancer skeletal metastases with parathyroid hormone
Q36678934Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review
Q64234600Prevention of tooth extraction-triggered bisphosphonate-related osteonecrosis of the jaws with basic fibroblast growth factor: An experimental study in rats
Q90713668Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw
Q39961852Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab
Q40612308Profile of bacteria colonizing the exposed bone of patients with anti-osteoclastic drug-related osteonecrosis of the jaws
Q58694636Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw
Q48517282Prosthetic versus surgical rehabilitation in patients with maxillary defect regarding the quality of life: systematic review
Q100634157Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone
Q50929134Quantitative ultrasound at the hand phalanges in patients with bisphosphonate-related osteonecrosis of the jaws.
Q37703472Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw.
Q39226186Radiographic evidence of treatment with bisphosphonates
Q57167005Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws
Q97528401Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review
Q64065276Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients
Q37689304Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw
Q39169596Relevance of Bisphosphonate Therapy in Osteoporosis and Cancer--No Cause for Alarm in Dentistry
Q90612928Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice
Q48510488Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function
Q38829698Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction
Q92118506Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
Q38457969Response to comments on "diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus".
Q42338856Response to letter to the Editors-Safety of long-term denosumab therapy
Q92272586Review and update on drugs related to the development of osteonecrosis of the jaw
Q39942547Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study
Q38705715Risk factors for medication-related osteonecrosis of the jaws: A systematic review.
Q64081652Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation
Q39162467Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer
Q92148335Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
Q48294628Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.
Q36345986Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Q51740878Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro.
Q45963261Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis?
Q47262486Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.
Q36433392Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla.
Q86297959Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series
Q50053219Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol
Q40973749Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw.
Q41036893Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report
Q42699567Successful Use of Lower-Level Laser Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaw.
Q40283265Successful treatment of osteonecrosis-induced fractured mandible with teriparatide therapy: A case report
Q35867314Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.
Q91642357Surgical resection for advanced bisphosphonate-related osteonecrosis of the jaw associated with fibrous dysplasia: a case report
Q51838456Surgical treatment of bisphosphonate-related osteonecrosis of the jaws with the use of buccal fat pad: case report.
Q48155186Surgical treatment of stage 2 medication-related osteonecrosis of the jaw compared to osteomyelitis.
Q38956113Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review.
Q38701111Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Q50585784Survey on awareness and perceptions of bisphosphonate-related osteonecrosis of the jaw in dental hygienists in Seoul.
Q61814521Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication)
Q64251161Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)
Q64071475Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication)
Q64251181Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication)
Q91933192Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice
Q92782550Task Force on Design and Analysis in Oral Health Research: Medication-Related Osteonecrosis of the Jaw
Q57300255The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention
Q89884796The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report
Q36292333The Prevention of Medication-related Osteonecrosis of the Jaw.
Q50061309The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw.
Q37181561The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection
Q90220979The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction
Q64880479The effect of bisphosphonate medication on orthodontics and orthognathic surgery in patients with osteogenesis imperfecta.
Q36560204The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells
Q35697018The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone
Q101038707The effect of pamidronate delivery in bisphosphonate-naïve patients on neutrophil chemotaxis and oxidative burst
Q35910376The effect of the duration of intravenous zolendronate medication on the success of non-surgical endodontic therapy: a retrospective study
Q90220861The effects of pentoxifylline and tocopherol in jaw osteomyelitis
Q55209360The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Q89418216The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay
Q41706770The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ).
Q92267711The role of bisphosphonates in orthodontic tooth movement-A review
Q39975608The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis
Q36107637The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.
Q41721635Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw.
Q64067509Three-dimensional bone evaluation after surgical treatment with plasma rich in growth factors of Medication Related Osteonecrosis of the Jaw (MRONJ): A report of 3 cases
Q38776007Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.
Q90447697Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis
Q92514549Tongue "heart" ulcer from bisphosphonate
Q38647544Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy
Q99552196Treatment of life-threatening acute osteomyelitis of the jaw during chemotherapy: a case report
Q51084874Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites.
Q37217775Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents.
Q40324652Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.
Q58578247Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review
Q42177129Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report
Q38979535Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review
Q36014948Usability of surgical treatment in cases of bisphosphonate-related osteonecrosis of the jaw stage 2 with sequestrum
Q57069083Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US
Q47911313Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis
Q87055716Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep
Q64236755Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis
Q46272591Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment
Q47559000Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis.
Q52857137[Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
Q93346859[Progress on medication-related osteonecrosis of the jaw]
Q87630095[Research progress on bisphosphonate-related osteonecrosis of the jaws]

Search more.